Overview

Iguratimod in Kidney Transplant Recipients

Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the effect of iguratimod concomitant with conventional immunosuppressive drugs on preventing antibody-induced rejection in HLA Highly mismatched Kidney Transplant recipients.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Treatments:
Glucocorticoids
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus